Possible metoprolol-induced hyperkalemia

Journal of Pharmacy Practice

Volumn 19, Issue 5, 2006, Pages 320-325

  Hawboldt, John ^a,c   McGrath, Debra ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Health Sciences Centre ^*

^c Health Sciences Centre St John's   (Canada)

Author keywords

Beta blockers; Chronic kidney disease; Diabetes; Hyperkalemia

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMAZEPAM; CANDESARTAN; CITALOPRAM; COLCHICINE; FELODIPINE; FOSINOPRIL; FUROSEMIDE; LEVOTHYROXINE; METOPROLOL; POLYSTYRENESULFONATE CALCIUM; POLYSTYRENESULFONATE SODIUM; ROSUVASTATIN;

AGED; ANAMNESIS; ANXIETY; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DEPRESSION; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; GOUT; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INSULIN DEFICIENCY; KIDNEY DYSFUNCTION; LOWER RESPIRATORY TRACT INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; RISK FACTOR; TREATMENT OUTCOME; URINARY EXCRETION; VITAL SIGN;

EID: 34248205021     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190007300728     Document Type: Article

References (42)

1. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health. (NIH publication No. 98-4080.)
2. Stevens FM, Dunlay RW Hyperkalemia in hospitalized patients. Int Urol Nephrol. 2000 ; 32: 170-180.
3. Shemer J., Ezra D., Modan M., Cabili S. Incidence of hyperkalemia in hospitalized patients. Isr J Med Sci. 1983 ; 19: 659-661.
4. Paice B., Gray Jmb, McBride D., Lawson DH Hyperkalemia in patients in hospital. BMJ. 1983 ; 286: 1189-1192.
5. Shapiro S., Slone D., Lewis GP, Jick H. Fatal drug reactions among medical inpatients. J Am Med Assoc. 1971 ; 271: 467-472.
6. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients. Arch Intern Med. 1998 ; 158: 917-924.
7. Borra S., Shaker R., Kleinfeld M. Hyperkalemia in an adult hospitalized population. Mt Sinai J Med. 1988 ; 55: 226-229.
8. Moore ML, Bailey RR Hyperkalemia in patients in hospital. N Z Med J. 1989 ; 102: 557-558.
9. Ahmed EU, Mohammed BN, Matute R., Burns GC Etiology of hyperkalemia in hospitalized patients: an answer to Harrinton's question. J Am Soc Nephrol. 1998 ; 9: 103A.
10. Perazella MA Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000 ; 109 (4). 307-314.
11. Faulkner M., Mears AJ, Adams PM, Frock JT, Dunlay RW Can selective beta-blockers be prescribed safely for hemodialysis patients? A retrospective review. Hosp Pharm. 2004 ; 39 (2). 144-148.
12. Canadian Adverse Drug Reaction Monitoring Program. CADRM Database. Ottawa, Ontario: Health Canada ; 2006.
13. Ponce SP, Jennings AE, Madias NE, Harrington JT Drug-induced hyperkalemia. Medicine. 1985 ; 64 (6). 357-370.
14. Cannon-Babb ML, Schwartz AB Drug induced hyperkalemia. Hosp Pract. 1986 ; 21 (9A): 99-107, 111, 114-127.
15. Elmfeldt D., Berglund G., Wedel H., Wilhelmsen L. Incidence and importance of metabolic side-effects during antihypertensive therapy. Acta Med Scand. 1983 (suppl); 672: 79-83.
16. Waal-Manning HJ Metabolic effects of beta-adrenoreceptor blockers. Drugs. 1976 ; 11 (suppl 1). 121-126.
17. Clausen T. Adrenergic control of Na+- K+-homeostasis. Acta Med Scand. 1983 (suppl); 672: 111-115.
18. Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs: an update. Drug Safety. 1993 ; 9 (4). 272-279.
19. Arthur S., Greenberg A. Hyperkalemia associated with intravenous labetolol therapy for acute hypertension in renal transplant recipients. Clin Nephrol. 1990 ; 33 (6). 269-271.
20. Hamad A., Salameh M., Zihlif M., Feinfeld DA, Carvounis CP Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol. 2001 ; 21 (3). 241-244.
21. McCauley J., Murray J., Jordan M., Scantlebury V., Vivas C., Shapiro R. Labetolol-induced hyperkalemia in renal transplant recipients. Am J Nephrol. 2002 ; 22 (4). 347-351.
22. Nowicki M., Miszczak-Kuban J. Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron. 2002 ; 91 (2). 222-227.
23. Ashouri OS Metoprolol-induced hyperkalemia in a diabetic with advanced renal failure. Arch Intern Med. 1985 ; 145 (3). 578.
24. Antrobus JH, Doolan LA, Bethune DW Hyperkalemia and myocardial atonia following cardioselective beta-blockade. J Cardiothorac Vasc Anesth. 1993 ; 7 (1). 76-78.
25. Rosa RM, Silva P., Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med. 1980 ; 302 (8). 431-434.
26. Halperin ML, Kamel KS Potassium. Lancet. 1998 ; 352: 135-140.
27. Gonick HC, Kleeman CR, Rubini ME, Maxwell MH Functional impairment in chronic renal disease. III. Studies of potassium excretion. Am J Med Sci. 1971 ; 261: 281-290.
28. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol. 1995 ; 6: 1134-1142.
29. Allon M., Takeshian A., Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int. 1993 ; 43: 212-227.
30. Classen T., Everets ME Regulation of the Na-K pump in skeletal muscle. Kidney Int. 1989 ; 35: 1-13.
31. Adrogué HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine. 1986 ; 65: 163.
32. Williams ME, Gervino EV, Rosa RM, et al. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med. 1985 ; 312 (13). 823-827.
33. Lundborg R. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand. 1983: 672 (suppl): 121-132.
34. Ewart HS, Klip A. Hormonal regulation of the Na(+)-K(+)-ATPase: mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol. 1995 ; 269 (2 Pt 1): C295 - C311.
35. Traub YM, Rabinov M., Rosenfeld JB, Treuherz S. Elevation of serum potassium during beta blockade: absence of relationship to the rennin-aldosterone system. Clin Pharmacol Ther. 1980 ; 28 (6). 765-7 68.
36. Schwartz AB, Cannon-Babb M. Hyperkalemia due to drugs in diabetic patients. Am Fam Physician. 1989 ; 39 (1). 225-231.
37. Castellino P., Bia MJ, DeFronzo RA Adrenergic modulation of potassium metabolism in uremia. Kidney Int. 1990 ; 37 (2). 793-798.
38. Williams ME Endocrine crises. Hyperkalemia. Crit Care Clin. 1991 ; 7 (1). 155-174.
39. Yang WC, Huang TP, Ho LT, Chung HM, Chan YL, Batlle DC Beta-adrenergic-mediated extrarenal potassium disposal in patients with end-stage renal disease: effect of propranolol. Miner Electrolyte Metab. 1986 ; 12 (3). 186-193.
40. Arrizabalaga P., Montoliu J, Martinez Vea A, Andreu L, Lopez Pedret J, Revert L. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc. 1983 ; 20: 572-576.
41. Repchisky C, ed. Compendium of Pharmaceuticals and Specialities. Ottawa: Canadian Pharmacists Association ; 2006.
42. Lexi-Comp Online, Lexi-Interact. Available at: www.uptodateonline.com. offcampus.lib.washington.edu/crlsql/interact/ frameset.jsp. Accessed September 27, 2006.